EMA Authorised: Bomyntra (denosumab) — Fresenius Kabi Deutschland GmbH

View source ↗

Summary

EMA authorises Bomyntra (denosumab) for therapeutic areas including neoplasms of bone tissue and giant cell tumor of bone.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Tumor of Bone
• Neoplasms of Bone Tissue

Drugs mentioned

• Bomyntra (denosumab)

Snippet

Status: Authorised. Therapeutic area: Neoplasms, Bone Tissue;Giant Cell Tumor of Bone. MAH: Fresenius Kabi Deutschland GmbH. Decision date: 09/07/2026